Syndax price target raised to $34 from $31 at Citi

Citi raised the firm’s price target on Syndax Pharmaceuticals to $34 from $31 and keeps a Buy rating on the shares. The firm says the AGAVE-201 data for axatilimab in chronic graft versus host disease look clinically meaningful. Citi sees a “strong case for approval.”